SCHEMBL15568713

SCHEMBL15568713

COC(=O)c1cc(Br)[nH]c1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.51
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 2/20 0.43
PDE3B Q13370 2/20 0.43
PDE3A Q14432 2/20 0.43
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NR4A2 P43354 4/20 0.41
XDH P47989 1/20 0.41
GAA P10253 3/20 0.41
GLA P06280 1/20 0.41
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA7 P43166 2/20 0.39
CA9 Q16790 2/20 0.39
CA14 Q9ULX7 2/20 0.39
PDK2 Q15119 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1157003 0.81 MAPT (0.65) MAPTKDM4EALDH1A1PDE3BPDE3A
SCHEMBL78402 0.80 MAPT (0.55) MAPTKDM4EALDH1A1PDE3BPDE3A
SCHEMBL31134834 0.77 MAPT (0.51) MAPTKDM4EALDH1A1PDE3BPDE3A
SCHEMBL15243917 0.77 ALDH1A1 (0.40) MAPTKDM4EALDH1A1LMNANR4A2
SCHEMBL25296768 0.74 MAPT (0.49) MAPTKDM4EALDH1A1PDE3BPDE3A
SCHEMBL10717495 0.74 MAPT (0.49) MAPTKDM4EALDH1A1PDE3BPDE3A
SCHEMBL10717450 0.74 MAPT (0.49) MAPTKDM4EALDH1A1PDE3BPDE3A
SCHEMBL7298645 0.74 MAPT (0.49) MAPTKDM4EALDH1A1PDE3BPDE3A
SCHEMBL4175783 0.73 PDE3B (0.60) MAPTKDM4EALDH1A1PDE3BPDE3A
SCHEMBL197110 0.70 SOS1 (0.50) MAPTKDM4EALDH1A1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
WO-2014025651-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 MAPT 727/4885KDM4E 2769/4885ALDH1A1 4469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.